Relay Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $74.1 million, a decrease from the $88.1 million loss recorded in the same period last year. For the nine months ending September 30, 2025, the company reported a net loss of $221.6 million, compared to a loss of $261.7 million for the same period in 2024. The company did not generate any revenue during the third quarter, maintaining total revenue of $8.4 million for the nine months, primarily from its collaboration with Elevar Therapeutics, which contrasts with $10 million from the Genentech Agreement in the previous year.
Operating expenses for the third quarter were $80.4 million, down from $96.4 million in the prior year, driven by a reduction in research and development costs, which fell to $68.3 million from $76.6 million. This decrease is attributed to strategic decisions made to streamline operations and a reduction in costs associated with the development of lirafugratinib following the Elevar Agreement. General and administrative expenses also decreased to $12.1 million from $19.8 million, reflecting lower stock compensation and employee-related costs.
In terms of operational developments, Relay Therapeutics continues to advance its clinical pipeline, including its lead product candidate RLY-2608, which is currently in clinical trials for various cancer indications. The company initiated a global Phase 3 trial, the ReDiscover-2 Trial, in June 2025, and is also conducting the ReInspire Trial for patients with PIK3CA-related overgrowth spectrum. The company has reported encouraging interim clinical data for RLY-2608, indicating potential efficacy in targeted patient populations.
As of September 30, 2025, Relay Therapeutics had cash, cash equivalents, and investments totaling $596.4 million, a decrease from $809.2 million at the end of 2024. The company anticipates that its existing resources will fund operations into 2029, although it acknowledges the need for additional capital to support ongoing clinical trials and potential commercialization efforts. Relay Therapeutics has not yet generated revenue from product sales and continues to rely on external financing to support its operations, highlighting the inherent risks associated with its business model in the biotechnology sector.
About Relay Therapeutics, Inc.
Relay Therapeutics is a biopharmaceutical company specializing in precision medicine through its Dynamo platform, which integrates computational and experimental techniques to target previously intractable proteins. Its focus includes oncology and genetic diseases, developing small molecule therapies such as mutant-selective kinase inhibitors. The company advances pipeline candidates, collaborates with partners like Pfizer and Elevar, and aims to deliver targeted, innovative treatments for life-threatening conditions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.